News

Tryp Therapeutics Inc. Announces Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3.0 Million

KELOWNA, BC / ACCESSWIRE / November 2, 2023 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP), a clinical-stage biotechnology…

8 months ago

AlzeCure Presents at Redeye Life Science Day on November 23

STOCKHOLM, SE / ACCESSWIRE / November 02, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…

8 months ago

Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 8, 2023

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release…

8 months ago

Protagonist Announces Achievement of $50M Milestone Event After Third Patient is Dosed in Phase 3 Study of JNJ-2113 in Moderate-to-Severe Psoriasis

NEWARK, CA / ACCESSWIRE / November 1, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the achievement…

8 months ago

Healthcare’s Outsourcing Boom on a Trajectory to Double by 2027, Black Book 20th Annual Industry Study

Management representatives from 1,428 provider organizations are electing to deflect mounting solution delivery concerns to outsourcing vendors, according to 91%…

8 months ago

Lotus Announces Fiscal Year Results

VANCOUVER, BC / ACCESSWIRE / November 1, 2023 / Lotus Ventures Inc. (CSE:J)(OTC:LTTSF) ("Lotus" or the "Company") a B.C. based…

8 months ago

Acclaimed Surgeon Pulls Back the Curtain on Life-Changing Liposculpture and Lipedema Surgery

BEVERLY HILLS, CA / ACCESSWIRE / November 1, 2023 / Dr. David Amron, board-certified dermatologic surgeon and renowned Lipedema specialist,…

8 months ago

Medigene presents new data for MDG2011, the first TCR in a novel KRAS library, demonstrating capability of its proprietary E2E Platform to generate multiple enhanced TCR-T therapies against mKRAS G12V A*11

Planegg/Martinsried, November 4, 2023. Medigene AG (Medigene, the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the…

8 months ago

Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023

Analysis of week 36 data from Phase 2b ORIGIN study shows atacicept 150 mg substantially reduces serum Gd-IgA1 and resolves…

8 months ago

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune…

8 months ago